4//SEC Filing
SEELEY BRUCE J. 4
Accession 0000891293-18-000088
CIK 0000891293other
Filed
Sep 19, 8:00 PM ET
Accepted
Sep 20, 5:25 PM ET
Size
5.4 KB
Accession
0000891293-18-000088
Insider Transaction Report
Form 4
SEELEY BRUCE J.
EVP, Chief Commercial Officer
Transactions
- Award
Non-Qualified Stock Option (right to buy)
2018-09-18+125,000→ 125,000 totalExercise: $1.88Exp: 2028-09-18→ Common Stock (125,000 underlying)
Footnotes (1)
- [F1]The stock options will fully vest upon the Compensation Committee's certification of the European Medicines Agency approval of the Marketing Authorization Application for Pacritinib, assuming that such approval occurs no later than September 30, 2019.
Documents
Issuer
CTI BIOPHARMA CORP
CIK 0000891293
Entity typeother
Related Parties
1- filerCIK 0001474462
Filing Metadata
- Form type
- 4
- Filed
- Sep 19, 8:00 PM ET
- Accepted
- Sep 20, 5:25 PM ET
- Size
- 5.4 KB